Clinical Trial Update: Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) [Phase 3]

View source ↗

Summary

An extension study in Phase 3 to evaluate the safety and tolerability of oral dersimelagon (MT-7117) in subjects with erythropoietic protoporphyria or X-linked …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria
• X-linked Protoporphyria

Drugs mentioned

• Dersimelagon (MT-7117)

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: EPP, XLP | Phase 3 | Status: RECRUITING